Acid-Related Upper Gastrointestinal Disorders in Women Using Alendronate for Ost
Acid-Related Upper Gastrointestinal Disorders in Women Using Alendronate for Osteoporosis
Detection, prevention, and treatment of osteoporosis (OSPS) have increased substantially with the advent of a variety of successful pharmacologic interventions. Among agents for prevention and treatment, alendronate is second only to hormone replacement therapy as a pharmacotherapeutic choice by clinicians. It is not uncommon that after extensive clinical use, a somewhat different side-effect profile of a new drug emerges than was delineated in pre-marketing studies. The current study evaluated the frequency of acid-related upper GI disorders (ARD) seen in alendronate users compared to non-users.
The study population included all recipients of alendronate who were discharged from a Kaiser Foundation Health Plan hospital with diagnosis of peptic ulcer, gastric ulcer, gastro-esophageal reflux disease, gastritis, esophagitis, dyspepsia nausea, vomiting, or abdominal pain during a 12 month period (n = 812), compared with nonusers of alendronate.
Users of alendronate were more than 1.5 times more likely to have an acid-related upper GI disorder than non-users; risk increased with age and concomitant use of NSAIDS.
Ettinger and associates conclude that alendronate is associated with an increased risk for acid-related upper GI disorders, suggesting a greater clinical vigilance for such consequences; they also suggest that inclusion of the cost of such drug-related adversities might well be included in computation of disease management.
Ettinger B, et al. J Am J Man Care 1998;4:377-1382.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.